title: Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia.
authors.forename: Joanne
authors.initials: J
authors.lastname: Craig
authors.forename: Katherine
authors.initials: K
authors.lastname: Walker
authors.forename: Mark
authors.initials: M
authors.lastname: Sales
authors.forename: Joan
authors.initials: J
authors.lastname: Cunningham
authors.forename: Keith
authors.initials: K
authors.lastname: Gelly
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Pippard
authors.forename: Sudhir
authors.initials: S
authors.lastname: Tauro
mesh_terms: D001549:Benzamides; D000069439:Dasatinib; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib